Your current web browser is outdated. For best viewing experience, please consider upgrading to the latest version.

Contact

Send a question or comment using the form below. This message may be routed through support staff.

Email Article

ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
ERROR
Main Error Mesage Here
More detailed message would go here to provide context for the user and how to proceed
search DONATE
Close Nav

The FDA’s Oversight of Drug and Vaccine Development: A Conversation with Richard Epstein

back to top
video

The FDA’s Oversight of Drug and Vaccine Development: A Conversation with Richard Epstein

December 9, 2020
Health PolicyFDA ReformDrug Development

Double-blind studies have been the gold standard in drug and vaccine development for decades. But should they be? Is the current regulatory regime saving or costing lives? Is there a way in which free market competition might improve upon the FDA’s tight-fisted control of the pharmaceutical development process?

Join us for this timely conversation with senior fellow James Copland and law professor Richard Epstein on drug and vaccine development, the limits of bureaucratic regulation, and the capacity of markets to share knowledge, control risk, and spur life-saving innovation.

Saved!
Close